LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Inicio・Lista de Acciones・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Cerrado

SectorSanidad

1.47 2.8

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.44

Máximo

1.47

Métricas clave
By Trading Economics
Ingresos	-16M -13M
Ventas	-15M 14M
BPA	-0.04
Margen de beneficios	-90.03
Empleados	103
EBITDA	-18M -12M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+175.69% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	22M 516M
Apertura anterior	-1.33
Cierre anterior	1.47

Noticias sobre sentimiento de mercado

By Acuity

39%

61%

116 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

0.6863 / 0.72 Soporte y Resistencia

Lexicon Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

14 nov 2025, 17:45 UTC

Ganancias

Principales Movimientos del Mercado

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14 nov 2025, 17:31 UTC

Ganancias

Principales Movimientos del Mercado

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

15 nov 2025, 18:03 UTC

Ganancias

Kugler Resignation From Fed Board Followed Disclosures of Improper Stock Trades -- UPDATED -- WSJ

15 nov 2025, 15:43 UTC

Ganancias

Kugler Resignation From Fed Board Followed Disclosures of Improper Stock Trades -- WSJ

15 nov 2025, 12:00 UTC

Ganancias

Meta Opens Pop-Up Stores to Build Buzz for Its AI Glasses -- WSJ

15 nov 2025, 09:20 UTC

Charlas de Mercado

Ganancias

Tech, Media & Telecom Roundup: Market Talk

15 nov 2025, 09:20 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

15 nov 2025, 00:08 UTC

Adquisiciones, fusiones, absorciones

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 3rd Update

14 nov 2025, 23:56 UTC

Adquisiciones, fusiones, absorciones

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14 nov 2025, 23:02 UTC

Charlas de Mercado

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14 nov 2025, 22:35 UTC

Ganancias

Adquisiciones, fusiones, absorciones

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14 nov 2025, 22:32 UTC

Adquisiciones, fusiones, absorciones

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14 nov 2025, 22:29 UTC

Ganancias

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14 nov 2025, 22:00 UTC

Adquisiciones, fusiones, absorciones

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14 nov 2025, 21:50 UTC

Charlas de Mercado

Ganancias

Tech, Media & Telecom Roundup: Market Talk

14 nov 2025, 21:18 UTC

Adquisiciones, fusiones, absorciones

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14 nov 2025, 20:27 UTC

Charlas de Mercado

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14 nov 2025, 20:23 UTC

Charlas de Mercado

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14 nov 2025, 20:17 UTC

Adquisiciones, fusiones, absorciones

Several State Attorneys General Oppose Railroad Merger -- WSJ

14 nov 2025, 19:29 UTC

Charlas de Mercado

Ganancias

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14 nov 2025, 18:44 UTC

Charlas de Mercado

Ganancias

Disney's Growth Now Hinges More on ESPN -- Market Talk

14 nov 2025, 18:27 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

14 nov 2025, 18:27 UTC

Charlas de Mercado

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14 nov 2025, 18:20 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14 nov 2025, 17:20 UTC

Charlas de Mercado

Ganancias

Auto & Transport Roundup: Market Talk

14 nov 2025, 17:20 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Health Care Roundup: Market Talk

14 nov 2025, 17:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

14 nov 2025, 16:51 UTC

Charlas de Mercado

Starbucks Gets Holiday Sales Lift -- Market Talk

14 nov 2025, 16:48 UTC

Charlas de Mercado

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

14 nov 2025, 16:38 UTC

Charlas de Mercado

Unica Reports Higher Brazilian Sugar and Ethanol Production -- Market Talk

Comparación entre iguales

Cambio de precio

Lexicon Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

175.69% repunte

Estimación a 12 Meses

Media 3.97 USD 175.69%

Máximo 6 USD

Mínimo 1.9 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Lexicon Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

3 ratings

Comprar

Mantener

Vender

De acuerdo con 3 analistas que ofrecen calificaciones bursátiles a para Lexicon Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

0.6863 / 0.72Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentimiento

By Acuity

116 / 374 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.